Jak Pharmalab Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 7 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.80 M
as on 17-12-2024
- Revenue -2.78%
(FY 2023)
- Profit -99.03%
(FY 2023)
- Ebitda 7.75%
(FY 2023)
- Net Worth 0.39%
(FY 2023)
- Total Assets 51.50%
(FY 2023)
About Jak Pharmalab
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.80 M.
Abhijit Chowdhary and Hasi Chowdhury serve as directors at the Company.
- CIN/LLPIN
U51909MH2017PTC292011
- Company No.
292011
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Jak Pharmalab Private Limited offer?
Jak Pharmalab Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Air Fresheners, Cosmetics, Hair & Beauty Products, Facial Kit, Herbal Soaps, Mosquito & Insect Repellent, Mosquito Repellent, Gifts, Crafts & Artifacts, Occasional Gift, Packaging Caps & Seals.
Who are the key members and board of directors at Jak Pharmalab?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhijit Chowdhary  | Director | 06-Mar-2017 | Current |
| Hasi Chowdhury | Director | 06-Mar-2017 | Current |
Financial Performance of Jak Pharmalab.
Jak Pharmalab Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.78% decrease. The company also saw a substantial fall in profitability, with a 99.03% decrease in profit. The company's net worth moved up by a moderate rise of 0.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jak Pharmalab?
Unlock access to Jak Pharmalab's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 14 Aug 2020 | ₹4.80 M | Open |
How Many Employees Work at Jak Pharmalab?
Unlock and access historical data on people associated with Jak Pharmalab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jak Pharmalab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jak Pharmalab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
